Statistical and ethical issues in the design and conduct of phase I and II clinical trials of new anticancer agents.
about
Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancersA population-based clinical trial of irinotecan and Carboplatin.Evaluation of lapatinib and topotecan combination therapy: tissue culture, murine xenograft, and phase I clinical trial dataA phase I study of tasisulam sodium (LY573636 sodium), a novel anticancer compound, administered as a 24-h continuous infusion in patients with advanced solid tumors.Pharmacokinetic/Pharmacodynamic modeling of abexinostat-induced thrombocytopenia across different patient populations: application for the determination of the maximum tolerated doses in both lymphoma and solid tumour patients.An innovative, multi-arm, complete phase 1b study of the novel anti-cancer agent tasisulam in patients with advanced solid tumors.Phase I trial of nedaplatin chemotherapy concurrent with radiotherapy for untreated locoregionally advanced nasopharyngeal carcinoma.Quality assessment of phase I dose-finding cancer trials: proposal of a checklist.Phase I oncology studies: evidence that in the era of targeted therapies patients on lower doses do not fare worseStopping rules employing response rates, time to progression, and early progressive disease for phase II oncology trials.What does a modified-Fibonacci dose-escalation actually correspond to?A phase I clinical trial of dose escalation of lobaplatin in combination with fixed-dose docetaxel for the treatment of human solid tumours that had progressed following chemotherapyA phase I study of tasisulam sodium (LY573636 sodium), a novel anticancer compound in patients with refractory solid tumorsPhase I clinical trial of the Src inhibitor dasatinib with dacarbazine in metastatic melanomaA statistical evaluation of dose expansion cohorts in phase I clinical trials.Adaptive Estimation of Personalized Maximum Tolerated Dose in Cancer Phase I Clinical Trials Based on All Toxicities and Individual Genomic ProfilePatients in phase I trials of anti-cancer agents in Japan: motivation, comprehension and expectations.Tolerability, pharmacokinetics, and serum bactericidal activity of intravenous dalbavancin in healthy volunteersPhase I studies of chemotherapeutic agents in cancer patients: a review of the designs.Evaluation of rodent-only toxicology for early clinical trials with novel cancer therapeutics.Cancer stem cells: relevance to SCTStochastic Approximation and Modern Model-based Designs for Dose-Finding Clinical Trials.Defining the research category in pediatric Phase I oncology trials.Safety and tolerability of transcranial direct current stimulation to stroke patients - A phase I current escalation study.Nature and subjectivity of dose-limiting toxicities in contemporary phase 1 trials: comparison of cytotoxic versus non-cytotoxic drugs.Assessing risk/benefit for trials using preclinical evidence: a proposal.Ethical and practical problems of early anti-cancer drug trials: a review of the literature.Investigating psychosocial aspects of participation in early anti-cancer drug trials: towards a choice of methodology.Treatment of advanced gastrointestinal cancer with genetically modified autologous mesenchymal stem cells - TREAT-ME-1 - a phase I, first in human, first in class trial.Evaluation of statistical designs in phase I expansion cohorts: the Dana-Farber/Harvard Cancer Center experience.A randomized phase I Bayesian dose escalation design for the combination of anti-cancer drugs.The association between treatment-specific optimism and depressive symptomatology in patients enrolled in a Phase I cancer clinical trial.Two Phase 1 dose-escalation studies exploring multiple regimens of litronesib (LY2523355), an Eg5 inhibitor, in patients with advanced cancer.Predictors for establishing recommended phase 2 doses: analysis of 320 dose-seeking oncology phase 1 trials.Bayesian nonparametric inference on the dose level with specified response rate.The quality of life of cancer patients participating in phase I clinical trials using SEIQoL-DW.Continual reassessment methods in phase I trials of the combination of two drugs in oncology.An exploration of relative health stock in advanced cancer patients.Investigator Disclosure and Advanced Cancer Patient Understanding of Informed Consent and Prognosis in Phase I Clinical TrialsThe continual reassessment method for dose-finding studies: a tutorial
P2860
Q27851426-721625A2-312C-4111-A0C4-4788BFBAE834Q33384279-5E3C516F-81F9-48CA-AD54-610F870A93B6Q33388617-BB10A4D5-1846-47D9-BADE-963D1AD02433Q33404760-82939708-1A43-4E73-A3F3-D2EE5D630432Q33415594-8533B260-52B6-4BE3-8FF7-295DC92F79ADQ33417869-66870B6D-F2D5-4442-9C92-5CBA603B7119Q33429679-E14B8C49-A87C-40B1-9273-39BDB92BA8F6Q33644414-D68835CC-98C0-4227-AD7C-41264C0EEE2DQ33658203-EA38A0AC-456D-4B3D-A04E-DC0CF0D5BB12Q34094103-842F680E-6698-4BB2-A0CA-B93159F07518Q34348422-E84C7BD0-70F9-4550-B88A-4B2F2B694633Q34583261-93F31C65-D5C4-4429-A0F5-C830C99F93CCQ35549459-FC893C4B-206D-4F10-9652-D9B146BF2BA7Q35653813-337A813C-C0FF-4DDD-8203-11E8840D47C7Q36047412-CBE13E25-742D-44C3-BC33-10EE0457A000Q36261042-F5C082EC-F2B8-46CA-A275-9CE720846FADQ36422375-2CBE7854-3EFE-46F9-B5AD-1EEE5E59F5A6Q36490252-D3079BD5-DA31-454C-8C22-4F2C11F8E712Q36621961-44EC69A5-EE8C-4EFF-9F92-FEC00CE7DF73Q36640945-7B56B1C9-1EE1-4536-83CD-7D6AC1C6F96DQ37398584-83289C9A-9B61-4DCD-AC86-D51D85DB2B7EQ37825427-25DA8A4A-794D-4D47-AA50-7D9DB3F4F24DQ38337650-EEA5780F-0E75-4852-8F3B-0FC8C9261C4EQ38379638-C98422F2-F25C-4093-8772-FAE5CCCB9421Q40354212-643C2427-5BB5-4C95-910A-3F57CD1DDF63Q40925322-CBCF0739-877D-4619-A31F-6F5C36E892FDQ41038564-A1AA074D-5EF9-4037-A46A-18021C28D5BFQ41738763-A9485B47-F60B-4159-A36C-97F7628BF589Q43063875-E69FA681-7360-4F8A-9859-9A412EA8C72AQ43846394-67E8B663-68F1-4DF6-B4E2-12DD45A40983Q45994896-D6BD08BB-FB47-4742-81F1-F7BDC2D9CF2BQ48677815-D7FB5B78-9F1B-4E83-B65D-C6F0358A2467Q51185142-A2B0599E-B0CD-4896-8B34-903CEEB2E8A7Q51640753-5328C851-1F1A-4B40-A3BE-E656D694A202Q52079392-20DC6EB5-5A58-4ECA-BA3F-51D18E7D1AB7Q52174950-528EFA69-54B2-4465-8A73-D8830D090391Q52209373-8EB16DE3-4585-4466-8931-39D77A541AC7Q53320303-6AAF38D4-5AC3-4399-AD88-91A123BA0A46Q56545806-7AB8E8DA-03FC-451E-AE15-77A0BD6225F2Q57338843-70A29D79-7330-4811-B707-172EE0D58E1F
P2860
Statistical and ethical issues in the design and conduct of phase I and II clinical trials of new anticancer agents.
description
1993 nî lūn-bûn
@nan
1993年の論文
@ja
1993年論文
@yue
1993年論文
@zh-hant
1993年論文
@zh-hk
1993年論文
@zh-mo
1993年論文
@zh-tw
1993年论文
@wuu
1993年论文
@zh
1993年论文
@zh-cn
name
Statistical and ethical issues ...... ials of new anticancer agents.
@en
type
label
Statistical and ethical issues ...... ials of new anticancer agents.
@en
prefLabel
Statistical and ethical issues ...... ials of new anticancer agents.
@en
P2093
P921
P356
P1476
Statistical and ethical issues ...... ials of new anticancer agents.
@en
P2093
P304
P356
10.1093/JNCI/85.20.1637
P407
P577
1993-10-01T00:00:00Z